Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | LTA4H | P09960 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282319 | 0.90 | MAPK1 (0.69) | RAB9AMAPK1LTA4HALDH1A1KMT2A | |
| SCHEMBL10679028 | 0.90 | RAB9A (0.89) | RAB9AMAPK1NPC1HRH3KCNH2 | |
| SCHEMBL1899201 | 0.85 | LTA4H (1.00) | RAB9ALTA4HNPC1HRH3KCNH2 | |
| Anisole SCHEMBL27860490 | 0.84 | DRD3 (0.64) | RAB9AMAPK1LTA4HALDH1A1KMT2A | |
| SCHEMBL14970484 | 0.84 | LTA4H (0.97) | RAB9ALTA4HNPC1HRH3KCNH2 | |
| SCHEMBL6658075 | 0.84 | LTA4H (0.68) | RAB9AMAPK1LTA4HNPC1HRH3 | |
| Anisole SCHEMBL27860438 | 0.83 | DRD3 (0.62) | RAB9AMAPK1LTA4HALDH1A1KMT2A | |
| SCHEMBL4237405 | 0.83 | LTA4H (0.72) | RAB9AMAPK1LTA4HNPC1HRH3 | |
| Fluorobenzene SCHEMBL27860496 | 0.82 | MAPK1 (0.59) | RAB9AMAPK1LTA4HALDH1A1KMT2A | |
| SCHEMBL11898739 | 0.81 | NPC1 (0.97) | RAB9ALTA4HNPC1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463731-A1 | DIBENZODIAZEPINE DERIVATES, THEIR PREPARATION AND USE | Abbott GmbH & Co. KG (DE) | 2004-10-06 | — | — | EP | disclosed |
| US-20030139394-A1 | Dibenzodiazepine derivatives, their preparation and use | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003057699-A1 | DIBENZODIAZEPINE DERIVATES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139394-A1 | Dibenzodiazepine derivatives, their preparation and use | CYP1B1, DRD1, CYP1A1 | RAB9A 1198/4885MAPK1 694/4885LTA4H 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.